Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs

Juvena Therapeutics, Inc. on Wednesday entered a global licensing and multi-target research collaboration with Eli Lilly And Co (NYSE:LLY).

The two companies aim to develop and commercialize drug candidates that improve muscle health and body composition.

Juvena will leverage JuvNET, an AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.

The collaboration will identify muscle-targeting drug candidates from Juvena's proprietary library of human stem-cell secreted proteins for improved body composition and muscle health.

Also Read: Eli Lilly’s Obesity Drug Success Spurs Japanese Biotech’s Anti-Muscle-Wasting Combo Therapy

Juvena Therapeutics is showcasing how its AI-driven discovery platform can accelerate the development of regenerative therapies for chronic diseases like obesity and frailty, Hanadie Yousef, co-founder ...